- Trial phase
- Phase 3 (completed)
- Time to market
- Mirum plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2027, supported by the positive AZURE-1 and AZURE-4 results. If accepted and approved, commercial launch could follow in late 2027 or early 2027.
- Why 6/10
- The next hard, dated catalyst is the planned BLA submission for brelovitug in HDV in H1 2027 (by June 30, 2027). This is a major regulatory milestone for a late-stage asset that is a significant value driver for Mirum, but Mirum also has substantial approved-product revenue (~$715-720M in 2026 net product sales) and a broader pipeline, so the company is not a single-asset binary.
Brelovitug has cleared its two pivotal Phase 3 trials (AZURE-1 and AZURE-4), setting up a BLA submission in H1 2027. The stock already reflects significant optimism (analyst mean target $155 vs ~$94 close), and the next major binary event is the BLA acceptance and subsequent FDA review. Watch for the AZURE-2 head-to-head data against Gilead's Hepcludex, which will determine brelovitug's commercial positioning in a market with one existing approved therapy.
Price Chart
Executive Summary
Brelovitug is Mirum Pharmaceuticals' investigational monoclonal antibody for chronic hepatitis delta virus (HDV), a rare and severe liver infection. The drug has now succeeded in two pivotal Phase 3 trials (AZURE-1 in September 2026 and AZURE-4 on November 10, 2026), both meeting their primary endpoints of combined virologic response and ALT normalization. Mirum acquired brelovitug through its January 2026 acquisition of Bluejay Therapeutics for up to $820M. The drug has FDA Breakthrough Therapy and Orphan Drug designations, and Mirum plans to submit a BLA in H1 2027. The main competition is Gilead's Hepcludex (bulevirtide), which received FDA accelerated approval in May 2026 as the first approved HDV treatment in the US. Mirum is already a profitable commercial-stage company with ~$715-720M in 2026 net product sales from its approved liver disease drugs.
How It Works
A fully human monoclonal antibody that binds to hepatitis B surface antigen (HBsAg), a protein on the surface of the hepatitis B virus that the hepatitis delta virus (HDV) needs to infect liver cells. By binding HBsAg, brelovitug neutralizes the virus and blocks HDV from entering and replicating in liver cells.
Trial Status
Two pivotal Phase 3 trials have both met their primary endpoints. AZURE-1 (Phase 2b/3) met its primary endpoint in September 2026, showing combined virologic response and ALT normalization at Week 24. AZURE-4 (Phase 3) met its primary endpoint on November 10, 2026, with 59% of patients receiving 300 mg once weekly achieving the combined endpoint at Week 24. Long-term data showed 100% virologic response and 100% ALT normalization in patients with cirrhosis following up to 108 weeks of treatment. A third Phase 3 trial, AZURE-2, comparing brelovitug head-to-head against Gilead's Hepcludex (bulevirtide, is ongoing.
The Two-Sided Case
Upcoming Catalysts
- BLA submission to FDA planned for H1 2027
- AZURE-2 head-to-head Phase 3 data vs Hepcludex (bulevirtide) - timing undisclosed
- Potential FDA Accelerated Approval pathway decision
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Mirum Pharmaceuticals, Inc. 8-K MIRM ·Originating report